1. OECD . Pharmaceutical spending. https://data.oecd.org/healthres/pharmaceutical-spending.htm. Accessed April 15, 2021.
Google Scholar2. Wenzel, M, Paris, V. Pharmaceutical reimbursement and pricing in Germany. https://www.oecd.org/health/health-systems/Pharmaceutical-Reimbursement-and-Pricing-in-Germany.pdf. Accessed April 15, 2021.
Google Scholar3. Krankenkassen Zentrale. Informationen zur Krankenversicherungspflicht in Deutschland. https://www.krankenkassenzentrale.de/wiki/krankenversicherungspflicht#. Accessed April 15, 2021.
Google Scholar4. GKV Spitzenverband. Die gesetzlichen Krankenkassen. https://www.gkv-spitzenverband.de/krankenversicherung/kv_grundprinzipien/alle_gesetzlichen_ krankenkassen/alle_gesetzlichen_krankenkassen.jsp. Accessed April 15, 2021.
Google Scholar5. Krankenkassen Zentrale. Private Krankenversicherung (PKV) – Vergleich. https://www.krankenkassenzentrale.de/liste/private-krankenversicherungen#. Accessed April 15, 2021.
Google Scholar6. Das Fünfte Buch Sozialgesetzbuch. Gesetzliche Krankenversicherung (SGB V) [Social Security Code V] of December 20, 1988, BGBl I at 2477, 2482, as last amended by Art. 1a of the law of December 22, 2020, BGBl I at 3299.
Google Scholar7. GKV Spitzenverband. Statutory health insurance. https://www.gkv-spitzenverband.de/english/statutory_health_insurance/statutory_health_insurance.jsp. Accessed April 15, 2021.
Google Scholar8. SGB V, ss 5–10.
Google Scholar9. SGB V, s 5(5).
Google Scholar10. Bundesministerium für Gesundheit. Arzneimittelmarktneuordnungsgesetz (AMNOG).https://www.bundesgesundheitsministerium.de/service/begriffe-von-a-z/a/arzneimittelmarktneuordnungsgesetz-amnog.html. Accessed April 15, 2021.
Google Scholar11. Robinson, JC, Panteli, D, Ex, P. Negotiating drug prices without restricting patient access: lessons from Germany. STAT. 2019. https://wahealthalliance.org/wp-content/uploads/2020/10/European-Drug-Pricing.pdf. Accessed May 3, 2021.
Google Scholar12. Robinson, JC, Panteli, D, Ex, P. Reference pricing in Germany: implications for U.S. pharmaceutical purchasing. Issue Brief (The Commonwealth Fund). 2019. https://www.commonwealthfund.org/sites/default/files/2019-02/Robinson_reference_pricing_germany_ib.pdf. Accessed May 3, 2021.
Google Scholar13. Robinson, JC, Ex, P, Pantelli, D. Drug price moderation in German: Lessons for U.S. Reform efforts. Issue Brief (The Commonwealth Fund). 2020. https://www.commonwealthfund.org/publications/issue-briefs/2020/jan/drug-price-moderation-germany-lessons-us-reform-efforts. Accessed May 3, 2021.
Google Scholar14. AMNOG, Art. 1 no. 5.
Google Scholar15. BT-Dr 17/2413.
Google Scholar16. See also Medicinal Products Act (Arzneimittelgesetz – AMG), s 48(1) sentence 1.
Google Scholar17. SGB V, s 35a(1) sentence 1.
Google Scholar18. See G-BA. English Version. https://www.g-ba.de/english. Accessed April 15, 2021.
Google Scholar19. SGB V, s 92.
Google Scholar20. SGB V, s 91(2) sentence 1.
Google Scholar21. SGB V, s 140f.
Google Scholar22. GKV-Modernisierungsgesetz.
Google Scholar23. SGB V, s 35a(7) sentence 1.
Google Scholar24. SGB V, s 35a(1) sentence 3.
Google Scholar25. SGB V, s 35a(1) sentences 2 and 3, (2).
Google Scholar26. SGB V, s 35a(3) sentence 2 in conjunction with s 92(3a) sentence 1.
Google Scholar27. SGB V, s 35a(3) sentence 1.
Google Scholar28. SGB V, s 130b(1) sentence 1.
Google Scholar29. SGB V, s 130b(4).
Google Scholar30. SGB V, s 35(3) sentence 1 and (5) sentence 1.
Google Scholar31. SGB V, s 35a(4) sentence 1.
Google Scholar32. Medicinal Product Benefit Assessment Ordinance (Arzneimittel-Nutzenbewertungsverordnung or AM-NutzenV) of December 28, 2010 Federal Law Gazette I, p. 2324), as last amended by Art. 13 of the Act of August 9, 2019 (Federal Law Gazette I, p. 1202), Section 7(4) sentence 5.
Google Scholar33. Interview with Professor Karl Lauterbach, member of the Bundestag, Berlin, May 15, 2018.
Google Scholar34. Interview with Hannah Brül and Stephanie Said, G-BA, May 17, 2018, Berlin.
Google Scholar35. Wieseler B, McGauran N, Kaiser T. New drugs: where did we go wrong and what can we do better? BMJ. 2019;10:366.
Google Scholar36. Rodwin MA. Pharmaceutical price and spending controls in France: lessons for the United States. International Journal of Health Services. 2020;50(2):156–165.
Google Scholar37. SGB V, s 130b(3a).
Google Scholar38. SGB V, s 130b(5).
Google Scholar39. SGB V, s 35a(5) sentences 1 and 4.
Google Scholar40. Greiner, W, Witte, J. AMNOG-Report 2018: Nutzenbewertung von Arzneimitteln in Deutschland. Medhochzwei Verlag GmbH; 2018.
Google Scholar41. Stern, AD, Pietrulla, F, Herr, A, Kesselheim, AS, Sarpatwari, A. The impact of price regulation on the availability of new drugs in Germany. Health Aff. 2019;38(7):1182–1187. 10.1377/hlthaff.2018.05142
Google Scholar | Crossref42. SGB V, s 35a(1) sentence 4.
Google Scholar43. SGB V, s 35(1) sentence 2.
Google Scholar44. Verband Forschender Arzneimittelhersteller e.V. Festbeträge schnell erklärt. https://www.vfa.de/de/wirtschaft-politik/abcgesundheitspolitik/festbetraege-schnell-erklaert. Accessed April 15, 2021.
Google Scholar45. Bundesministerium für Gesundheit. Zuzahlung und Erstattung von Arzneimitteln. https://www.bundesgesundheitsministerium.de/zuzahlung-und-erstattung-arzneimittel.html. Accessed April 15, 2021.
Google Scholar46. SGB V, s 35(5) sentence 4.
Google Scholar47. German Federal Institute for Drugs and Medical Devices . List of reference prices for medicinal products. https://www.dimdi.de/dynamic/en/drugs/reference-pricing. Accessed April 15, 2021.
Google Scholar48. Section 5(2) of the framework agreement under Section 130b(9) of the SGB V. https://www.gkv-spitzenverband.de/media/dokumente/krankenversicherung_1/arzneimittel/rahmenvertraege/pharmazeutische_unternehmer/Rahmenvereinbarung_130b_Abs9__SGB_V_2016.pdf. Accessed April 15, 2021.
Google Scholar49. SGB V, s 139a.
Google Scholar50. The AM-NutzenV defines the term “benefit” as “the patient-relevant therapeutic effect, in particular with regard to the improvement of the health status, the shortening of the duration of illness, the extension of survival, the reduction of side effects, or an improvement of the quality of life.” AM-NutzenV, Section 2(3).
Google Scholar51. An “added benefit” is a benefit that “is quantitatively or qualitatively higher than the benefit of the appropriate comparator therapy.” AM-NutzenV, Section 2(4).
Google Scholar52. AM-NutzenV, Section 5(7) no.1–3.
Google Scholar53. AM-NutzenV, Section 5(7) no.4.
Google Scholar54. AM-NutzenV, Section 5(7) no.5.
Google Scholar55. AM-NutzenV, Section 5(7) no.6.
Google Scholar56. AM-NutzenV, §§ 5(4), 7(2).
Google Scholar57. G-BA. Zusatznutzen neuer Arzneimittel. https://www.g-ba.de/themen/arzneimittel/arzneimittel-richtlinie-anlagen/nutzenbewertung-35a/zusatznutzen. Accessed April 15, 2021.
Google Scholar58. See also IQWIG. Allgemeine Methoden (Version 6). https://www.iqwig.de/methoden/allgemeine-methoden_version-6-0.pdf?rev=180500
Google Scholar59. Interview with Professor Reinhard Busse, Berlin, May 14, 2018.
Google Scholar60. Email correspondence from Beate Wieseler, Head of Department, Dept. Drug Assessment, IQWIG, February 8, 2021.
Google Scholar61. Fischer, KE, Stargardt, T. Early benefit assessment of pharmaceuticals in Germany: manufacturers’ expectations versus the Federal Joint Committee’s decisions. Med Decis Making. 2014;34(8):1030–1047. doi.org/10.1177/0272989X14546377
Google Scholar | SAGE Journals | ISI62. SGB V, s 35a(1) sentence 11.
Google Scholar63. SGB V, s 35a(1c).
Google Scholar64. SGB V, s 35a(1) sentence 5.
Google Scholar65. SGB V, 130b(3) sentence 1.
Google Scholar66. SGB V, 130b(1) sentence 7.
Google Scholar67. Section 5(1) of the framework agreement under Section 130b(9) of the SGB V. https://www.gkv-spitzenverband.de/media/dokumente/krankenversicherung_1/arzneimittel/rahmenvertraege/pharmazeutische_unternehmer/Rahmenvereinbarung_130b_Abs9__SGB_V_2016.pdf. Accessed April 15, 2021.
Google Scholar68. Section 5(3) of the framework agreement under Section 130b(9) of the SGB V. https://www.gkv-spitzenverband.de/media/dokumente/krankenversicherung_1/arzneimittel/rahmenvertraege/pharmazeutische_unternehmer/Rahmenvereinbarung_130b_Abs9__SGB_V_2016.pdf Accessed April 15, 2021.
Google Scholar69. SGB V, s 130b(9) sentence 3.
Google Scholar70. Section 6 and Annex 2 of the framework agreement under Section 130b(9) of the SGB V. https://www.gkv-spitzenverband.de/media/dokumente/krankenversicherung_1/arzneimittel/rahmenvertraege/pharmazeutische_unternehmer/Rahmenvereinbarung_130b_Abs9__SGB_V_2016.pdf. Accessed April 15, 2021.
Google Scholar71. Interview with Beate Wieseler, Berlin, May 14–16, 2018.
Google Scholar72. SGB V, s 130a(1) sentence 1.
Google Scholar73. SGB V, s 130a(1) sentence 2.
Google Scholar74. SGB V, s 130a(3b).
Google Scholar75. SGB V, s 130a(3).
Google Scholar76. SGB V, s 130a(8).
Google Scholar77. Bundesministerium für Gesundheit. Finanzergebnisse der GKV. www.bundesgesundheitsministerium.de/themen/krankenversicherung/zahlen-und-fakten-zur-krankenversicherung/finanzergebnisse.html. Accessed April 15, 2021.
Google Scholar78. Busse, R, Blümel, M, Knieps, F, Bärnighausen, T. Statutory health insurance in Germany: a health system shaped by 135 years of solidarity, self-governance, and competition. The Lancet. 2017;390(10097):882–897. doi.org/10.1016/S0140-6736(17)31280-1
Google Scholar79. Busse, R, Riesberg, A. Health Care Systems in Transition. WHO Regional Office for Europe on behalf of the European Observatory on Health Systems and Policies; 2004. https://www.euro.who.int/data/assets/pdf_file/0018/80703/E85472.pdf. Accessed May 3, 2021.
Google Scholar80. Busse, R, Schreyögg, J, Henke, KD. Regulation of pharmaceutical markets in Germany: improving efficiency and controlling expenditures? Int J Health Plann Manage. 2005;20(4):329–349. doi. 10.1002/hpm.818
Google Scholar | Crossref | Medline81. Lipton, HL, Kreling, DH, Collins, T, Hertz, KC. Pharmacy benefit management companies: dimensions of performance. Annu Rev Public Health. 1999;20:361–401. doi.org/10.1146/annurev.publhealth.20.1.361
Google Scholar | Crossref | Medline | ISI82. Shepherd, J . Pharmacy benefit managers, rebates, and drug prices: conflicts of interest in the market for prescription drugs. Yale Law Policy Rev. 2019;38(2):360–396.
Google Scholar83. Bai, G, Sen, AP, Anderson, GF. Pharmacy benefit managers, brand-name drug prices, and patient cost sharing. Ann Intern Med. 2018;168(6):436–437. doi.org/10.7326/M17-2506
Google Scholar | Crossref | Medline84. Brook, T, Roygardner, L, Artiga, S. Medicaid and CHIP eligibility, enrollment, and cost sharing policies as of January 2020: findings from a 50-state survey. https://www.kff.org/coronavirus-covid-19/report/medicaid-and-chip-eligibility-enrollment-and-cost-sharing-policies-as-of-january-2020-findings-from-a-50-state-survey. Accessed April 15, 2021.
Google Scholar85. 42 U.S.C. § 1396r-8 (k)(1)(A).
Google Scholar86. MACPAC. Medicaid payment for outpatient prescription drugs. https://www.macpac.gov/publication/medicaid-payment-for-outpatient-prescription-drugs. Accessed April 15, 2021.
Google Scholar87. Dolan, R, Marina, T. Pricing and payment for medicaid prescription drugs. Kaiser family foundation. Issue Brief, January 2020. https://www.kff.org/medicaid/issue-brief/pricing-and-payment-for-medicaid-prescription-drugs/. Accessed May 3, 2021.
Google Scholar88. Rome BN, Kesselheim AS. Will ending the medicaid drug rebate cap lower drug prices? JAMA Internal Medicine. 2021;181(8):1034–1035. doi:10.1001/jamainternmed.2021.2696.
Google Scholar | Crossref89. Centers for Medicare and Medicaid Services, Medicaid Pharmacy Supplemental Rebate Agreements (SRA) . As of December 2020. https://www.medicaid.gov/medicaid-chip-program-information/by-topics/prescription-drugs/downloads/xxxsupplemental-rebates-chart-current-qtr.pdf. Accessed April 15, 2021.
Google Scholar90. Hayes, JM, Walczak, H, Prochazka, A. Comparison of drug regimen costs between the medicare prescription discount program and other purchasing systems. JAMA. 2005;294(4):425–428. doi. 10.1001/jama.294.4.427-b
Google Scholar | Crossref91. Kaiser Family Foundation . An overview of medicare. Accessed April 15, 202. https://www.kff.org/medicare/issue-brief/an-overview-of-medicare
Google Scholar92. Social Security Act (SSA) §1860D-11(i).
Google Scholar93. McAdams, D, Schwarz, M. Perverse incentives in the medicare prescription drug benefit. Inq: J Health Care Organ Provision Financing. 2007;44(2):157–166. doi.org/10.5034/inquiryjrnl_44.2.157
Google Scholar94. Neumann, PJ . Using cost-effectiveness analysis to improve health care: opportunities and barriers. Oxford University Press; 2004.
Google Scholar | Crossref95. Medicaid.gov. Medicaid drug rebate program. https://www.medicaixfd.gov/medicaid/prescription-drugs/medicaid-drug-rebate-program/index.html. Accessed April 15, 2021.
Google Scholar96. Bach, PB . Limits on medicare’s ability to control rising spending on cancer drugs. NEJM. 2009;360(6):626–633. doi.10.1056/NEJMhpr0807774
Google S